CapitolRadar tracks every publicly disclosed TVTX trade by US congress members and corporate insiders: 0 disclosed trades (0 buys, 0 sells) by 0 tracked traders. Updated daily from official filings.
Want a ping when Congress buys TVTX? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Travere Therapeutics, Inc. (TVTX) — Healthcare · Biotechnology, market cap about $4.7B.
Cluster watch: 8 distinct tracked traders disclosed buying TVTX in the last 45 days: Meckler Jeffrey A (director), ROTE WILLIAM E. (officer: Chief Research Officer), Heerma Peter (officer: EVP, CHIEF COMMERCIAL OFFICER), Inrig Jula (officer: EVP, Head of R&D & CMO), REED ELIZABETH E (officer: Chief Legal Officer and GC), Dube Eric M (director, officer: CHIEF EXECUTIVE OFFICER).
CapitolRadar signal history
NEW PICK 2026-09-20
Travere CFO Christopher Cline reportedly bought 20,000 TVTX shares for about $348,800, joining a cluster of recent insider buyers. The panel passed mainly because the reported trade is future-dated and has not been verified against the underlying SEC Form 4. A valid Form 4 confirming the date, price, and open-market purchase would have materially strengthened the case.
NEW PICK 2026-09-20
Travere Therapeutics CEO and director Eric Dube reportedly bought about $4.57 million of TVTX stock, alongside several other insiders. The panel passed mainly because the listed September 2026 trade date is in the future, so the transaction could not be reliably verified. A confirmed regulatory filing with a valid trade date, share count, and purchase price would have addressed the key concern.
NEW PICK 2026-09-20
Travere executive Peter Heerma disclosed buying about $185,517 of TVTX, joining a recent cluster of insider buyers. The trade fell short mainly because its apparently future-dated 2026 transaction date makes the signal unreliable, despite the cluster. A verified SEC filing confirming the correct date and that this was a completed open-market purchase would have strengthened the case enough to reconsider it.
NEW PICK 2026-09-20
Travere Therapeutics Chief Research Officer William Rote disclosed buying about $850,300 of TVTX stock. The panel passed mainly because he has no verified trading history versus the S&P 500, so this sizable purchase remains an unproven signal despite other recent insider buyers. A verified record of similar purchases followed by sustained market outperformance would have supported a different verdict; the main caveat is that past results would still not guarantee future gains.
NEW PICK 2026-09-11
Travere Therapeutics director Jeffrey A. Meckler disclosed buying 10,000 TVTX shares for about $265,200. The trade fell short mainly because he has no verified trading history, so the insider signal is unproven; a documented record of outperforming SPY on prior purchases would have strengthened the case. The biggest caveat is that the trade-date price comparison is unavailable, making the stock’s run-up since the purchase unclear.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 …
Frequently asked questions
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.